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symptoms (Brief Symptom Inventory), psychosocial func-
tioning (Outcome Questionnaire-45) and quality of life (EQ-
5D), using multilevel statistical modelling. As the study was 
non-randomised, the propensity score method was used to 
control for initial differences.  Results: Patients in the day 
hospital and inpatient group improved substantially in terms 
of psychiatric symptoms, social and interpersonal function-
ing, and quality of life. Patients in the outpatient group 
showed less improvement. Direct comparison of the im-
provement of psychiatric symptoms showed significant re-
sults in favour of day hospital (p = 0.046) and inpatient (p = 
0.01) treatment, as compared to outpatient treatment. How-
ever, due to substantial baseline differences, this direct com-
parison should be judged carefully.  Conclusions: Cluster A 
psychopathology is not a contraindication to benefit from 
psychotherapy. This is especially true for more intensive 
forms like inpatient and day hospital treatment. Future re-
search should focus more on psychotherapeutic treatment 
to gain further insight into effective treatment options for 
this patient group.  Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Background: While psychopharmacological studies are 
common in patients with cluster A personality disorders, the 
effects of psychotherapy have received little attention. The 
aim of this study is to explore whether psychotherapeutic 
treatment yields health gains for these patients.  Methods: 
The study was conducted between March 2003 and June 
2008 in 6 mental health care centres in the Netherlands, with 
a sample of 57 patients with a DSM-IV-TR axis II cluster A di-
agnosis. Patients were assigned to 3 settings of psychother-
apeutic treatment (outpatient, day hospital, inpatient), and 
effectiveness was assessed at 18 months after baseline. An 
intention-to-treat analysis was conducted for psychiatric 
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 Introduction 
 Paranoid, schizoid and schizotypal personality disor-
ders (PD) are associated with significant psychological 
and functional impairment and a poor long-time prog-
nosis  [1–6] . Estimates for their prevalence in the general 
population range from 1.6 to 4.1%  [7–9] ; in psychiatric 
outpatients they are even more common (5.6–13.2%  [1, 
10] ). Therefore, it is important to investigate which treat-
ment forms can produce significant and long-lasting im-
provement in the life of these patients.
 Psychotherapy is recommended as the treatment of 
choice for patients with PD in general  [11] . More specifi-
cally, clinical experts suggest psychotherapy as the first 
treatment option for cluster A PD patients  [12–14] . Yet, 
psychotherapy effectiveness studies on the ‘odd’ cluster A 
PD are rare. Most existing studies investigate the impact 
of cluster A PD on treatment effects of axis I treatments 
or focus on the effectiveness of psychopharmacological 
treatment of schizotypal PD. It has been shown in these 
studies that the presence of cluster A PD, especially 
schizotypal PD, has a negative influence on the outcome 
of axis I treatments of both medical and psychotherapeu-
tic kind  [15–19] . Medication studies of schizotypal PD 
have shown that typical and atypical antipsychotics, and 
possibly antidepressants, can have a positive influence on 
distinguished  symptoms , such as cognitive disturbance, 
derealisation, ideas of reference, anxiety, self-image, so-
cial and overall functioning, odd communication, obses-
sive-compulsive symptoms and self-injury  [20–29] . The 
influence of medication on depressive symptoms in 
schizotypal patients is still controversial  [20, 22, 24, 25] . 
There is no ‘agent of choice’  [30] , and medication side ef-
fects are common, especially in typical neuroleptics  [21] . 
Moreover, it is repeatedly stated that whatever the value 
of pharmacological treatment may be, the quality of the 
therapeutic relationship is one of the most crucial aspects 
in the treatment of cluster A PD patients  [26] .
 Possible reasons for the paucity of research in this pa-
tient group might be the fact that cluster A PD patients 
seldom seek help from the psychiatric profession and the 
lack of consensus among clinicians about the effective-
ness of psychotherapy in this patient population  [14, 31] .
 This lack of consensus is maintained because the few 
effectiveness studies of psychotherapy in cluster A PD pa-
tients show contradicting results. Plakun et al.  [32] stud-
ied former inpatients at the ‘Austin Riggs Center’ of whom 
43 had a cluster A PD. They were classified into 4 groups: 
(1) pure schizotypal PD patients (n = 13), (2) combined 
borderline and schizotypal PD patients (n = 6), (3) com-
bined borderline with schizoid PD patients (n = 5), and 
(4) pure schizoid PD patients (n = 19). They found the 
highest improvement of general functioning in the com-
bined borderline and schizotypal PD group. After a fol-
low-up period of 14 years, this group functioned signifi-
cantly better than the comparison group of schizophren-
ic patients, with a Global Assessment Scale score  [33] of 
72.0. The other 3 cluster A PD groups also improved in 
their Global Assessment Scale score, but still functioned 
at a level comparable to schizophrenic patients at follow-
up, with mean Global Assessment Scale scores between 
55.6 and 66.6.
 In their studies on day hospital treatment, a Norwe-
gian research group found poor results regarding psychi-
atric symptoms and psychosocial functioning for pa-
tients with schizotypal PD (n = 9, with or without comor-
bid borderline PD)  [34, 35] . Their study sample also 
included patients with paranoid PD (n = 4) and schizoid 
PD (n = 5), but their results were not reported separately. 
The same holds true for the small group of cluster A PD 
patients (n = 4) in a study of Winston et al.  [36] . On the 
other hand, Gude and Vaglum  [37] in their study on in-
patients found no differences in improvement of psychi-
atric symptoms and occupational status between pure 
cluster A PD patients (n = 21) and both pure cluster B and 
pure cluster C patients. However, their sample of cluster 
A PD patients included only few patients with schizotyp-
al PD.
 The largest study reporting on cluster A PD patients is 
the study on day hospital treatment conducted by Kar-
terud et al.  [38] . Their sample contained 132 cluster A PD 
patients (treatment completers; n = 16 for schizotypal PD 
as ‘main’ diagnosis, n = 8 for schizoid PD and n = 108 for 
paranoid PD), including cluster A PD patients with co-
morbid cluster B and/or C PD. Their findings indicated 
that patients with cluster A PD had a high dropout rate
in day hospital treatment (23.9%) and that patients with 
paranoid and schizotypal PD showed only modest treat-
ment gains regarding psychiatric symptoms, quality of 
life and overall functioning. Patients with paranoid PD 
and comorbid borderline PD had significantly worse re-
sults at the 1-year follow-up than patients with borderline 
PD alone. As the group of patients with schizoid PD was 
too small, their follow-up results were not reported.
 Given that psychotherapy studies in cluster A PD pa-
tients are scarce and the evidence is conflicting, it is im-
portant to investigate further if psychotherapy can bring 
about change for these vulnerable patients. There are sub-
stantial differences between treatment options in terms 
of time and money. That makes it relevant for both pa-
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tients and society to know which setting of psychothera-
py (outpatient, day hospital or inpatient treatment) is suf-
ficiently efficient to produce positive change. Yet, no 
study has compared the outcomes of different treatment 
settings for patients with cluster A PD.
 The aim of the present study is to explore the effects of 
psychotherapy on patients with cluster A PD. More spe-
cifically, we want to answer the following research ques-
tions: (1) What is the change in psychiatric symptoms, 
social and interpersonal functioning, and quality of life 
in patients with cluster A PD 18 months after baseline? 
(2) What is the effect of different treatment settings, i.e. 
outpatient, day hospital and inpatient treatment?
 Methods 
 In this study we used a prospective naturalistic study design. 
To correct for the influence of selection bias due to non-randomi-
sation, we used the propensity score method (see below). For de-
tails of the method section, we refer to our earlier studies on clus-
ter C and B PD patients  [39, 40] .
 Participants 
 Participants (n = 57) were recruited from consecutive admis-
sions to 6 mental health care centres in the Netherlands. The in-
stitutions offer outpatient, day hospital and/or inpatient psycho-
therapeutic treatment for patients with personality pathology. 
From March 2003 to March 2006, 1,379 patients completed the 
intake and screening procedure and were selected for treatment 
( fig. 1 ). The intake and screening data were collected for all appli-
cants, irrespective of study participation later on. The data ob-
tained from this initial assessment served as baseline data for our 
study. As it was part of the standard screening procedure, in-
formed consent for the baseline data collection was not manda-
tory under Dutch law.
 Of these 1,379 patients, 146 (10.6%) were excluded from the 
study for not meeting one of the following inclusion criteria: age 
between 18 and 70 years (n = 13), significant personality pathol-
ogy (n = 34) and referral for psychotherapeutic treatment aimed 
at personality problems (n = 99). Nine patients (0.7%) met one of 
the following exclusion criteria: insufficient command of the 
Dutch language (n = 6), organic cerebral impairment (n = 1), men-
tal retardation (n = 1) and schizophrenia (n = 1). This left 1,224 
participants, of whom 31 (2.5%) could not participate due to lo-
gistic reasons. A total of 133 patients (10.9%) had to be excluded 
due to missing or unreliable baseline data during the intake and 
screening procedure. For the majority of these 133 patients (n = 
106), no standardised axis II diagnosis was obtained. This was 
mostly due to a practical problem, i.e. a shortage of interviewers 
at the start of the study (n = 101). Because of this logistic reason, 
it can be assumed that these data were ‘missing completely at ran-
dom’ and therefore they do not threaten internal validity (as they 
were unrelated to specific patient characteristics). Five patients 
had an unreliable axis II diagnosis as determined by the inter-
viewer. A few patients did not return their assessment booklet 
during the intake procedure (n = 27). Thirty-eight patients (3.1%) 
received less than 2 treatment sessions of outpatient therapy or 
less than 2 days of inpatient or day hospital therapy. They were 
therefore excluded beforehand from the study sample in which we 
only included patients with a ‘minimal effective dose’ of treat-
ment. One hundred patients (8.2%) refused to participate. The 
remaining 922 patients were informed about the study and its 
procedure, provided written informed consent and entered the 
study. Of those, 71 patients (7.7%) had 1 or more cluster A PD. 
 In the absence of explicit guidelines for treatment assignment 
in PD  [41] , the treatment selection procedure was based on the 
expert opinion of clinicians who used their clinical experience 
combined with patient data from standardised instruments. To 
clarify the criteria used for the assignment process, our research 
group had recently conducted a study with intake clinicians from 
the participating treatment centres. We found evidence of sub-
stantial consensus among clinicians concerning the criteria used 
for treatment decision making. Variables guiding the treatment 
selection process include the focality of problems, ego strength, 
symptom severity, psychological mindedness, relational capaci-
ties and quality of defence mechanisms  [42] .
 The 71 cluster A PD patients were assigned to 1 of 3 setting 
groups, based on the regular treatment assignment done by expert 
clinicians at the clinical sites: 24 patients to outpatient, 27 patients 
to day hospital and 20 patients to inpatient treatment. Follow-up 
data were not available for 14 patients (19.7%). There was no dif-
ference in psychiatric symptoms at baseline between patients with 
follow-up data and those without. The final sample consisted of 
57 patients who were included in the analyses.
 Treatment 
The 6 mental health care centres offer a variety of psychother-
apeutic treatments tailored to a PD patient population. Their 
treatments differ according to several features. As this study fo-
cused on different treatment settings, the following 3 treatment 
groups were compared: (1) Patients in outpatient treatment (n = 
20, 35.1% of the study sample). These patients came for individu-
al (75.0%) or group (25.0%) psychotherapy sessions for up to 2 
sessions/week (mean 1.0 session/week, SD 0.6, median 0.9; mean 
treatment duration 13.3 months, SD 6.2, median 12.0). Four 
health care centres offered outpatient treatment. (2) Patients in 
day hospital treatment (n = 19, 33.3% of the study sample). These 
patients came at least 1 morning/afternoon per week (mean 3.3 
days/week, SD 1.6, median 3.0) and received different forms of 
psychotherapeutic and psychosocial treatment, but slept at home 
(mean treatment duration 10.3 months, SD 4.5, median 9.0). Five 
health care centres offered day hospital treatment. (3) Patients in 
inpatient treatment (n = 18, 31.6% of the study sample). These pa-
tients stayed at the institutions 5 days a week and received differ-
ent forms of psychotherapeutic and psychosocial treatment (mean 
treatment duration 8.6 months, SD 2.4, median 8.5). Three health 
care centres offered inpatient treatment. 
 Outpatient treatments consisted of individual or group psy-
chotherapy sessions of various theoretical orientations (50% 
eclectic, 20% psychodynamic, 20% cognitive-behavioural, 10% 
other). Day hospital and inpatient programmes typically consist-
ed of group psychotherapy as a core element, mostly in combina-
tion with 1 or more non-verbal or expressive group therapies, in-
dividual psychotherapy, sociotherapy within the therapeutic 
community, coaching for social problems, community meetings 
and/or pharmacological treatment. The therapists were all li-
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censed psychiatrists or psychologists. On average, they had 14.9 
years (SD = 10.1) of postgraduate clinical experience. The treat-
ments under study can be considered highly representative of reg-
ular clinical practice in the Netherlands, as therapists did not re-
ceive specific training for this study and treatment integrity was 
not monitored. The study protocol was approved by the Medical 
Ethics Committee of the Erasmus University Medical Centre in 
Rotterdam.
 Assessments 
Baseline Measures. An extensive standard assessment battery 
of instruments was administered to the patients before treatment 
assignment. PD were measured using the Dutch version of the 
Structured Interview for DSM-IV Personality  [43, 44] .  To mea-
sure patient characteristics at baseline, the assessment battery 
also included 3 self-report instruments. The first of those was the 
Dutch version of the Dimensional Assessment of Personality Pa-
thology Basic Questionnaire, for measuring type and degree of 
personality pathology  [45, 46] . We used patient scores on this 
questionnaire on the 4 higher-order factors: emotional dysregula-
tion, dissocial behaviour, inhibition and compulsivity. To mea-
sure the severity of personality pathology, we used the 5 higher-
order domains of the Severity Indices of Personality Problems, 
Dutch version: self-control, social concordance, identity integra-
tion, relational capacities and responsibility  [47] . To measure the 
patients’ motivation for treatment, we used the 2 scales of the Mo-
Assessed for eligibility
n = 1,379
Enrolled
n = 960
Outpatient
treatment
n = 24
Day hospital
treatment
n = 27
Inpatient
treatment
n = 20
Refused to participate
n = 100
Excluded due to other reasons
n = 164
(logistic reasons n = 31,
missing/unreliable data n = 133)
Did not meet inclusion criteria
n = 146
Met exclusion criteria
n = 9
No DSM-IV Cluster A PD
diagnosis
n = 851
Lost to follow-up
n = 4
Lost to follow-up
n = 8
Lost to follow-up
n = 2
Analyzed
n = 20
Analyzed
n = 19
Analyzed
n = 18
Dropped out prematurely1
n = 38
Allocated
n = 71
 Fig. 1. Patient flow.  1  These patients did not 
receive a ‘minimal effective dose’ of treat-
ment, defined as 2 sessions for outpatients 
and 2 treatment days for day hospital pa-
tients or inpatients, and were therefore not 
included in the initial study sample. 
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tivation for Treatment Questionnaire: need for help and readiness 
to change  [48] .
 Outcome Measures.  The primary outcome measure was gen-
eral psychiatric symptomatology. This was measured using the 
Dutch version of the Brief Symptom Inventory  [49, 50] , a validat-
ed self-report scale derived from the Revised Symptom Checklist 
90  [51, 52] . In this study, we used the mean score of the 53 items 
of the Brief Symptom Inventory, i.e. the Global Severity Index 
(GSI), ranging from 0 to 4, with higher scores indicating more 
problems. Psychosocial functioning was measured with 2 sub-
scales of the 45-item Outcome Questionnaire (OQ-45), Dutch 
version: (1) interpersonal relations and (2) social role functioning 
 [53] . The total scores of these 2 scales range between 0 and 44, and 
between 0 and 36, respectively, with higher scores indicating 
more problems. Health-related quality of life was measured using 
2 scales of the Dutch version of the EuroQol questionnaire EQ-5D 
 [54] , with higher scores indicating a higher quality of life: the EQ-
5D index, which represents the societal value (i.e. the valuation of 
a particular health state as rated by the society) of quality of life 
with a value between 0 and 1, and the EQ visual analogue scale 
(EQ-VAS) which represents the patient’s own value of quality of 
life on a scale from 0 to 100. All 5 outcome measures, GSI, OQ-45 
social role, OQ-45 interpersonal relations, EQ-5D index and EQ-
VAS, were assessed at baseline and several follow-up moments. 
Three of the 6 treatment centres conducted their follow-up mea-
surements at 12, 24 and 36 months after baseline; the other 3 treat-
ment centres conducted their follow-up measurements at the end 
of treatment, subsequently 6 and 12 months after that, and again 
at 36 months after baseline. The use of different assessment points 
was due to logistic reasons in the participating centres. As some 
follow-up points were related to the end of treatment and treat-
ment duration varied considerably, we had no common measure-
ment point for all patients to determine mid-term outcome. This 
was taken into account by choosing multilevel modelling as the 
statistical method for the analyses. Multilevel modelling enabled 
us to make use of all the available data collected for every patient 
at multiple assessment points between baseline and 36 months 
and to reliably estimate change at 18 months.
 Statistical Analyses 
 We first examined the uncorrected results on all 5 outcome 
measures estimated at 18 months after baseline, thus without ap-
plying the propensity score method. We used multilevel model-
ling to deal with (1) the dependency of repeated measures on the 
same subject in time and (2) longitudinal data with observations 
unequally spaced in time (see ‘Outcome Measures’). To estimate 
the uncorrected treatment effect at 18 months after baseline, we 
used a random intercept and random slope model with time as 
level I and patient number as level II. This resulted in a model with 
the following independent variables: dummy variables indicating 
treatment group membership, time, and interaction between 
group membership and time. In these analyses, we used all avail-
able follow-up data from baseline to 36 months, but since we fo-
cused on mid-term outcome, we used the estimated change scores 
at 18 months after baseline, based on the results of the model. 
Subsequently, we calculated within-group effect sizes (Cohen’s d) 
 [55] to describe change from baseline to 18 months per treatment 
group (outpatient, day hospital, inpatient).
 However, treatment groups cannot be compared directly 
based on the uncorrected results in this non-randomised clinical 
trial as these findings might be confounded by initial patient dif-
ferences. To adjust for these differences and to avoid bias in effect 
estimation, we used the propensity score method. The classic pro-
pensity score is defined as the conditional probability of assign-
ment to 1 of 2 treatment groups given a set of observed pretreat-
ment variables  [56] . Propensity scores are used to reduce selection 
bias by equating groups based on these variables. Since we had to 
compare 3 treatment groups, we included a ‘multiple propensity 
Table 1. V ariables used for propensity score estimation, outcome GSI
Variable Content
DAPP-BQ Emotional dysregulation Unstable affective responding, interpersonal problems
DAPP-BQ Compulsivity Compulsivity and absence of oppositional behaviour
MTQ-8 Need for help Patient’s expressed desire for external help
SIPP Self-control Capacity to tolerate, use and control one’s own emotions and impulses
OQ-45 Symptom distress Level of symptom distress
OQ-45 Relational functioning Level of interpersonal functioning
SIDP-IV Cluster B PD Number of cluster B PD
SIDP-IV Cluster C PD Number of cluster C PD
SIDP-IV Dimensional score cluster B PD Dimensional score of cluster B PD characteristics
SIDP-IV Dimensional score cluster C PD Dimensional score of cluster C PD characteristics
SIDP-IV Total dimensional score Total dimensional score of PD characteristics
Drug abuse History of drug abuse
Borderline PD Diagnosis of borderline PD
Narcissistic PD Diagnosis of narcissistic PD
D APP-BQ = Dimensional Assessment of Personality Pathology – Basic Questionnaire; MTQ-8 = Motivation for Treatment Ques-
tionnaire; SIPP = Severity Indices of Personality Problems; OQ-45 = Outcome Questionnaire-45; SIDP-IV = Structured Interview for 
DSM-IV Personality.
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score’ in our analysis. The multiple propensity score is an exten-
sion of the classic propensity score to more than 2 treatment 
groups  [57] . To identify relevant confounders, we considered a 
long list of social, economic and diagnostic variables carefully se-
lected by both clinicians and researchers, based on the literature 
and clinical knowledge  [58] . All variables significantly related to 
a specific outcome were used to estimate the multiple propensity 
scores in a multinomial regression analysis, with group member-
ship as a dependent variable (for the variables included in the GSI 
propensity score, see  table 1 ; complete list of potential/identified 
confounders for all outcome variables available upon request). A 
major advantage of the propensity score method, as compared to 
other correction techniques, is the fact that the overlap in propen-
sity score distributions (and thus the overlap in relevant variables) 
between treatment groups can be easily judged and visualised 
 [59] . If the distribution of propensity scores shows large overlap 
in the different treatment groups, the groups are readily compa-
rable. If, however, overlap is insufficient, groups differ too much 
and their direct comparison might yield results which cannot un-
equivocally be attributed to a treatment effect. For a detailed de-
scription of the propensity score method and its use in psycho-
therapy research, see Bartak et al.  [58] and Spreeuwenberg et al. 
 [59] .
 To compare change in outcome variables across treatment 
groups adjusted for baseline patient characteristics, a more so-
phisticated multilevel model, now including multiple propensity 
scores, was used. Dependent variables were all available change 
scores observed during follow-up for each of the outcome mea-
sures. The following independent variables were entered in the 
initial model: dummy variables indicating group membership, 
time, the multiple propensity scores and their interactions. Then 
independent variables were eliminated from the model by back-
ward selection to obtain a final best-fit model. This model esti-
mated differences in change scores at 18 months after baseline in 
pair-wise comparisons of the 3 treatment groups.
 Follow-up response was high, enhancing the robustness of the 
estimations at 18 months: 77.2% of the patients had 3 or more 
follow-up measurements between baseline and 36 months. The 
analyses were performed using SPSS 17.0 for data preparation and 
Proc Mixed of SAS 9.1.3 for multilevel modelling (SAS Institute 
Inc., Cary, N.C., USA).
 Results 
 Sample Characteristics 
 Of the 57 patients, 70.2% were female ( table  2 ). The 
mean age was 29.4 years (SD = 8.2), and 78.9% were un-
married. The level of education was low for 43.9%, me-
dium for 10.5% and high for 45.6%. The majority (86.0%) 
had a diagnosis of paranoid PD. Only a minority (15.8%) 
had pure cluster A PD, while the remaining patients had 
cluster A PD and comorbid cluster B and/or C PD.
 As can be seen in  table 2 , patients in the 3 treatment 
groups differed substantially on a number of baseline 
variables. Significant differences appeared in age, marital 
status, baseline severity of psychiatric symptoms and 
baseline severity of quality of life. These substantial dif-
ferences complicate the adjustment of the results with the 
propensity score. Indeed, the overlap in the distribution 
of propensity scores was imperfect ( fig. 2 ), and the results 
of these 3 groups of patients were not readily comparable, 
even after applying propensity score correction. One has 
to keep that in mind when judging possible group differ-
ences in change scores.
 Treatment Compliance 
 Before start of treatment, every patient received an al-
location to a certain ‘treatment dosage’ in terms of setting 
and duration. According to our registration at the end of 
treatment, about one quarter of all patients (n = 14) un-
derwent exactly the intended treatment regarding both 
setting and exact duration (25.0% of the outpatient group, 
31.6% of the day hospital group and 16.7% of the inpatient 
group), and 94.7% of the patients (n = 54) stayed in the 
assigned setting group (100.0% of the outpatient group, 
94.7% of the day hospital group and 88.9% of the inpa-
tient group). Of the 43 patients whose received treatment 
duration deviated from their intended treatment dura-
tion, 17 (39.5% of the deviating patients) stayed in treat-
ment shorter than planned (40.0% of the deviating pa-
tients in the outpatient group, 46.2% in the day hospital 
group and 33.3% in the inpatient group). Of these 17 pa-
tients, 10 decided in agreement with their therapist that 
treatment was no longer beneficial or necessary, whereas 
7 patients dropped out of treatment prematurely or were 
forced to leave earlier by the staff. From these 7 dropouts, 
1 patient was from the outpatient group (5.0% of the total 
outpatient group), 4 patients were from the day hospital 
group (21.1% of the total day hospital group), and 2 pa-
tients were from the inpatient group (11.1% of the total 
inpatient group). All dropouts were treatment dropouts 
(and no study dropouts) who completed follow-up mea-
surements and were included in the intention-to-treat 
analyses.
 Treatment Outcome 
 Patients in the day hospital and inpatient groups 
showed larger improvements than patients in the out-
patient group ( table 3 ;  fig. 3 ), when inspecting the effect 
sizes for the 3 different treatment groups without propen-
sity score correction. More specifically, patients of the day 
hospital and inpatient groups showed significant im-
provement after 18 months in terms of psychiatric symp-
toms (GSI), the primary outcome measure (p  ! 0.0001), 
whereas patients of the outpatient group did not (p = 
0.16).
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 Significant improvements for patients from the day 
hospital and inpatient groups were also observed for so-
cial and interpersonal functioning (OQ-45) and for qual-
ity of life (EQ-5D index and EQ-VAS). The single out-
come measure with significant improvements after 18 
months for patients of the outpatient group was OQ-45 
social role (p = 0.02). The difference between the outpa-
tient group on the one hand and the day hospital and in-
patient groups on the other hand was especially striking 
for the EQ-VAS score. Patients in the outpatient group 
started healthier and hardly improved (effect size = 0.04), 
whereas patients in the day hospital and inpatient groups 
started treatment less healthy and subsequently improved 
substantially with effect sizes of 1.03 and 0.74, respec-
tively.
 Group Comparisons of Different Settings 
 The group comparisons corrected with the propensity 
score method confirmed the superiority of day hospital 
and inpatient treatment in terms of improvement of psy-
chiatric symptoms (GSI), as can be seen in  table 4 . After 
correction for observed pretreatment differences by 
means of the multiple propensity score, the differences in 
improvement between outpatient and day hospital treat-
ment and between outpatient and inpatient treatment 
proved to be significant with   = 0.52 (p = 0.046) and
Table 2. B aseline characteristics
Variable Outpatient
(n = 20)
Day hospital
(n = 19)
Inpatient
(n = 18)
Total
(n = 57)
Gender, %
Male 40.0 10.5 38.9 29.8
Female 60.0 89.5 61.1 70.2
Age*, years 33.688.6 28.288.0 25.986.1 29.488.2
Education, %
Low 55.0 57.9 16.7 43.9
Medium 10.0 10.5 11.1 10.5
High 35.0 31.6 72.2 45.6
Marital status*, %
Unmarried 60.0 84.2 94.4 78.9
Married 20.0 15.8 5.6 14.0
Widowed/divorced 20.0 0.0 0.0 7.0
Child care, %
Yes 30.0 10.5 5.6 15.8
No 70.0 89.5 94.4 84.2
Cluster A PD diagnosis, %
Paranoid PD 90.0 94.7 72.2 86.0
Schizoid PD 5.0 5.3 16.7 8.8
Schizotypal PD 5.0 5.3 11.1 7.0
PD diagnosis, %
‘Pure’ cluster A 15.0 10.5 22.2 15.8
Cluster A + B 20.0 0.0 16.7 12.3
Cluster A + C 40.0 31.6 22.2 31.6
Cluster A, B + C 25.0 57.9 38.9 40.4
GSI* 1.480.7 2.080.6 2.080.8 1.880.8
OQ-45 Social role 15.784.7 18.885.4 17.785.5 17.485.3
OQ-45 Interpersonal relations 21.485.5 23.786.5 25.584.7 23.585.8
EQ-5D index* 0.780.2 0.480.3 0.580.3 0.680.3
EQ-VAS 61.9818.4 55.4819.1 53.2816.5 57.0818.1
Psychotropic medication, %
Yes 60.0 63.2 55.6 59.6
No 40.0 36.8 44.4 40.4
R esults are expressed as percentages or as means 8 SD, as indicated. * p ≤ 0.05: significant group differ-
ences.
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  = 0.73 (p = 0.01), respectively. The differences in im-
provement of psychiatric symptoms between day hospital 
and inpatient treatments were minimal, with   = 0.22
(p = 0.41).
 Group differences in the improvement of psychosocial 
functioning were smaller than the differences in the im-
provement of psychiatric symptoms, with results that 
were far from significant. The same holds true for the dif-
ferences in change scores of the EQ-5D quality of life in-
dex. However, the difference in change scores of the EQ-
VAS between outpatient and day hospital treatments was 
statistically significant (  = 23.82; p = 0.02), favouring 
day hospital treatment.
 Taken together, the corrected results suggest most of all 
a superiority of day hospital and inpatient treatment, as 
compared to outpatient treatment, with regard to the im-
provement of psychiatric symptoms 18 months after base-
line. However, as mentioned above, these results have to 
be interpreted cautiously as it appeared from the limited 
overlap of propensity score distributions that the 3 patient 
groups consisted of substantially different patients.
 Discussion 
 Main Findings 
 This study examined the effect of psychotherapy on 
patients with cluster A PD. The most important conclu-
sion is that cluster A personality pathology per se does not 
seem to be an impediment to benefit from psychothera-
peutic treatment.
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 Fig. 2. Overlap in propensity score distributions, outcome GSI. 
Figures near symbols indicate case numbers of outliers. 
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Table 3. U ncorrected outcomes (means 8 SD) and effect sizes in 3 treatment groups for all outcome variables
Variable Treatment group Baseline 18 months Within-group
effect size,
Cohen’s d
GSI Outpatient (n = 20) 1.3780.68 1.1680.88 0.27
Day hospital (n = 19) 1.9980.62 1.1480.69 1.33
Inpatient (n = 18) 1.9780.82 1.0180.73 1.27
OQ-45 Outpatient (n = 20) 15.6884.68 11.9786.23 0.69
Social role Day hospital (n = 19) 18.8485.36 13.1285.26 1.11
Inpatient (n = 18) 17.7485.54 11.3886.33 1.10
OQ-45 Outpatient (n = 20) 21.3985.50 18.6589.41 0.36
Interpersonal relations Day hospital (n = 19) 23.6786.50 17.9187.40 0.85
Inpatient (n = 18) 25.5284.74 17.3188.12 1.27
EQ-5D index Outpatient (n = 20) 0.6780.19 0.7680.20 0.47
Day hospital (n = 19) 0.4580.28 0.6780.25 0.85
Inpatient (n = 18) 0.5380.30 0.6980.26 0.59
EQ-VAS Outpatient (n = 20) 61.90818.36 62.55817.20 0.04
Day hospital (n = 19) 55.42819.09 72.06813.72 1.03
Inpatient (n = 18) 53.17816.48 66.13819.31 0.74
Table 4. C omparison of change scores from baseline to 18 months after propensity score correction, all outcome 
variables
Variable Treatment groups compared  value 95% CI p value
GSI Outpatient (n = 20) vs. day hospital (n = 19) 0.52 0.01 to 1.03 0.046
Outpatient (n = 20) vs. inpatient (n = 18) 0.73 0.16 to 1.30 0.01
Day hospital (n = 19) vs. inpatient (n = 18) 0.22 –0.31 to 0.74 0.41
OQ-45 Outpatient (n = 20) vs. day hospital (n = 19) –0.58 –4.89 to 3.73 0.79
Social role Outpatient (n = 20) vs. inpatient (n = 18) 0.97 –3.24 to 5.18 0.65
Day hospital (n = 19) vs. inpatient (n = 18) 1.55 –2.42 to 5.53 0.44
OQ-45 Outpatient (n = 20) vs. day hospital (n = 19) 0.68 –4.41 to 5.76 0.79
Interpersonal Outpatient (n = 20) vs. inpatient (n = 18) 2.87 –2.27 to 8.02 0.27
relations Day hospital (n = 19) vs. inpatient (n = 18) 2.20 –2.50 to 6.89 0.35
EQ-5D index Outpatient (n = 20) vs. day hospital (n = 19) 0.01 –0.12 to 0.15 0.83
Outpatient (n = 20) vs. inpatient (n = 18) 0.03 –0.11 to 0.16 0.68
Day hospital (n = 19) vs. inpatient (n = 18) 0.01 –0.11 to 0.14 0.83
EQ-VAS Outpatient (n = 20) vs. day hospital (n = 19) 23.82 3.92 to 43.72 0.02
Outpatient (n = 20) vs. inpatient (n = 18) –0.20 –36.39 to 36.00 0.99
Day hospital (n = 19) vs. inpatient (n = 18) –24.01 –61.88 to 13.85 0.21
 values: positive coefficients indicate that the last treatment group shown is superior, negative coefficients 
indicate that the first treatment group is superior. CI = Confidence interval.
 Psychotherapy for Cluster A Personality 
Disorder 
Psychother Psychosom 2011;80:88–99 97
 The majority of the study sample presented with a di-
agnosis of paranoid PD and showed high comorbidity 
with the 2 other PD clusters. When comparing the 3 
treatment groups, it appeared that – with regard to psy-
chiatric symptoms – patients in the day hospital and in-
patient groups improved more than patients in the out-
patient group.
 Strengths and Limitations 
 Strengths of the present study are its considerable 
sample size for a cluster A PD population and its natural-
istic design, which made it possible to gain insight into 
treatments as given in daily clinical practice. Further-
more, the attempt of powerful statistical control of poten-
tial confounders, using the multiple propensity score 
methodology, is unique in the cluster A literature.
 Nevertheless, this study also had limitations. First, due 
to substantial baseline differences of patients in the 3 
treatment groups, a direct comparison of the 3 settings 
was difficult to conduct. Higher treatment gains cannot 
readily be attributed to a certain treatment, as variables 
other than treatment group might have played a role. That 
outpatients improve less may be due to the fact that they 
are older at the start of treatment or have a heavier burden 
of care responsibilities at home. The present study cannot 
rule out that patient characteristics played a role in the ex-
planation of the results, as overlap of propensity score dis-
tributions was limited. Second, even though we controlled 
for all observed pretreatment differences, it cannot be 
ruled out that results were influenced by other, unob-
served confounders. To minimise this last risk as much as 
possible, a broad range of possible confounders was care-
fully selected and measured, based on both clinical and 
empirical knowledge  [58] . If related to outcome, these 
variables were included in the propensity score. Third, the 
majority of patients had a diagnosis of paranoid PD which 
makes its results mainly applicable to this diagnostic 
group and to a lesser extent to patients with schizotypal 
and schizoid PD. Fourth, the high comor bidity with other 
PD clusters makes it questionable to attribute the treat-
ment gains to an improvement in cluster A pathology. Pos-
sibly the improvement observed in our study is due to ad-
vances made in a different area of psychiatric impairment. 
Nevertheless, the main conclusion stays valid: improve-
ment in different areas of life is possible for patients with 
cluster A PD who undergo psychotherapeutic treatment.
 Clinical Significance 
 The differences in improvement between outpatients 
on the one hand and day hospital and inpatients on the 
other hand are striking, especially compared to the poor 
results of day hospital treatment in cluster A PD patients 
found by Karterud et al.  [38] . These authors found an ef-
fect size of 0.23 (versus 1.33 in the present study), when 
measuring change in GSI scores of paranoid and schizo-
typal patients from baseline to follow-up (1 year after dis-
charge with a mean treatment duration of  8 5 months, 
i.e. comparable to our 18 months after baseline). Might 
day hospital and inpatient treatment nevertheless be the 
preferable treatment options for this patient group? The 
present data suggest this conclusion, especially because 
these patients start off worse compared to outpatients 
and seem to improve more during treatment. Moreover, 
this effect cannot be explained by the influence of drop-
out rates, as treatment compliance was even lower in the 
day hospital (21.1% dropout rate) and inpatient group 
(11.1% dropout rate) compared to the outpatient group 
(5.0% dropout rate). The day hospital dropout rate is com-
parable to the one of Karterud et al.  [38] (23.9%). One 
possible explanation for the differences between the two 
studies might be that our treatment duration was twice 
as long as the one of Karterud et al. Maybe cluster A pa-
tients need a longer treatment duration to experience 
change. A complication is that regression to the mean 
might also explain a part of the observed effect, as the 
patients with the highest baseline severity showed the 
highest improvement. For ethical reasons we were not 
able to compare our findings to a control group receiving 
no treatment at all. Clearly, more research is needed to 
further elucidate these findings before drawing major 
conclusions. The only conclusion we can draw from our 
findings with confidence is that cluster A pathology does 
not seem to be a contraindication for psychotherapy.
 Implications for Research and Public Health 
 What are the implications of the present results for fu-
ture research, clinical practice and public health policy?
 We found that cluster A pathology does not seem to 
form an impediment for psychotherapeutic treatment 
and that gains in different areas of life can be observed in 
patients with cluster A PD. Bearing the limitations of this 
pioneering study in mind, this might be the first step to-
wards a revised vision of this patient group in mental 
health practice. Some 20 years ago, patients with border-
line PD were considered as ‘untreatable’, whereas now a 
multitude of treatment protocols have been developed for 
this patient group and research on their implementation 
showed encouraging results  [60–62] . The same could be 
true for cluster A PD patients. An important question for 
further treatment research for this patient population is: 
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are more intensive treatments such as day hospital and 
inpatient treatment indeed the treatment of choice for 
cluster A PD patients as our results seem to suggest, and, 
if yes, how can they be tailored to this population?
 Now that we presume that cluster A pathology does 
not necessarily interfere with psychotherapeutic treat-
ment, cluster A PD patients should not a priori be exclud-
ed from psychotherapy. On the contrary, if our results 
can be replicated, it would be important to make psycho-
therapy more accessible for this patient group in order to 
reach health gains for this vulnerable group of psychiatric 
patients. Concluding, clinical practice may be more opti-
mistic regarding psychotherapeutic treatment in cluster 
A PD patients.
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